RxDoctor Payments Data

Cody Rowan, MD

Pain Medicine · Dawsonville, GANPI 1013165331

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $4,640 of the $5,696 with a category attached, or 81.5%. 12 manufacturers reported payments, led by Medtronic at 57.4% of the total. Reporting peaked in 2022 at $2,289 and has fallen 84.1% since, to $363 in 2025.

$5,696in general payments, 2019–2025

Across 81 payments — averaging $70.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$3K
  • Boston Scientific$1K
  • Nevro Corp.$748
  • Abbott$292
  • SPR Therapeutics, Inc$120
  • Curonix LLC$98
  • plus $151 from 6 others

What the payments were for

  • Travel & lodging$1,05619%
  • Food & beverage$4,64081%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,696 in reported general payments places this provider in the 70th percentile of 203 pain medicine providers in Georgia.

See all pain medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$232,347
Medicare patients
344
Services billed
4,101

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Buprenorphine134$35,089
BelbucaBuprenorphine Hcl25$16,515
Gabapentin756$7,524
Pregabalin265$3,860
Naloxone Hcl44$3,170
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen209$2,959
Tramadol Hcl ErTramadol Hcl15$1,526
Methocarbamol104$1,507
Baclofen122$1,470
Cyclobenzaprine Hcl145$1,397
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen76$1,389
Tramadol Hcl216$1,002
Duloxetine Hcl68$791
Diclofenac Sodium51$598
Tizanidine Hcl49$333

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca$19$16,51525 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 203 pain medicine providers in Georgia.

Other pain medicine in Dawsonville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →